Shire PLC's acceptance, as expected, of a £48.17 per share acquisition offer from determined pursuer Takeda Pharmaceutical Co. Ltd., paves the way for a roughly £46bn ($62.45bn) deal that will create a new force just inside the global pharma top 10, and also marks both the biggest ever M&A transaction by the Japanese pharma sector and the largest overseas buy-out in any sector in Japan.
Takeda Grabs Shire At Last After Long Pursuit
Takeda and Shire see their £46bn combination bringing commercial and pipeline strengths across multiple therapeutic areas, along with opportunities for cost synergies and strengthening in key geographic markets.
